Gregory Vladimer, PhD, is co-founder and CEO of Graph Therapeutics, a Vienna-based techbio company combining primary patient immune cells with machine learning to discover new medicines for inflammatory and immune-mediated diseases. He trained as an immunologist, earning his PhD at UMass Chan Medical School before a postdoc at CeMM in Vienna focused on functional drug discovery in blood cancers. He went on to co-found Allcyte, a CeMM spin-off that pioneered AI-driven functional precision oncology and was acquired by Exscientia in 2021, and then served as VP Translational Research through Exscientia’s IPO and large commercial pharma partnerships. He was named a 2023 Endpoints News LGBTQ+ Biotech Leader and his platform technology was awarded numerous Prix Galien awards between 2022 and 2024.
